131 related articles for article (PubMed ID: 19797936)
1. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor.
Palwai NR; Zang XP; Harrison RG; Benbrook D; Pento JT
Pharmacology; 2009; 84(5):271-5. PubMed ID: 19797936
[TBL] [Abstract][Full Text] [Related]
2. Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Palwai NR; Zang XP; Harrison RG; Pento JT
Anticancer Res; 2007; 27(5A):3435-9. PubMed ID: 17970092
[TBL] [Abstract][Full Text] [Related]
3. Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Peron K; Jones TN; Gauthier SA; Nguyen TN; Zang XP; Barriere M; Prévéraud D; Soliman CE; Harrison RG; Pento JT
Cancer Chemother Pharmacol; 2003 Oct; 52(4):270-6. PubMed ID: 12827296
[TBL] [Abstract][Full Text] [Related]
4. Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration.
Zang XP; Palwai NR; Lerner MR; Brackett DJ; Pento JT; Harrison RG
Anticancer Res; 2006; 26(3A):1745-51. PubMed ID: 16827102
[TBL] [Abstract][Full Text] [Related]
5. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
6. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
Su M; Chang W; Wang D; Cui M; Lin Y; Wu S; Xu T
Oncol Rep; 2015 Sep; 34(3):1337-44. PubMed ID: 26166362
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
8. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
9. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
10. A novel tumor-activated ALA fusion protein for specific inhibition on the growth and invasion of breast cancer cells MDA-MB-231.
Liu X; Liu X; Sunchen S; Liu M; Shen C; Wu J; Zhao W; Yu B; Liu J
Drug Deliv; 2017 Nov; 24(1):1811-1817. PubMed ID: 29172777
[TBL] [Abstract][Full Text] [Related]
11. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.
Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM
Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143
[TBL] [Abstract][Full Text] [Related]
12. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect and mechanism of action of a tumor-targeting recombinant human tumor necrosis factor-α fusion protein mediated by urokinase.
Dai YC; Yang SM; Wang X; Zhou YJ; Hou G; Huang DN
Mol Med Rep; 2015 Jun; 11(6):4333-40. PubMed ID: 25672264
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
Zuppone S; Assalini C; Minici C; Bertagnoli S; Branduardi P; Degano M; Fabbrini MS; Montorsi F; Salonia A; Vago R
Sci Rep; 2020 Feb; 10(1):2521. PubMed ID: 32054892
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1.
Lamfers ML; Grimbergen JM; Aalders MC; Havenga MJ; de Vries MR; Huisman LG; van Hinsbergh VW; Quax PH
Circ Res; 2002 Nov; 91(10):945-52. PubMed ID: 12433840
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
17. Scalable Production of Recombinant Membrane Active Peptides and Its Potential as a Complementary Adjunct to Conventional Chemotherapeutics.
Rothan HA; Ambikabothy J; Abdulrahman AY; Bahrani H; Golpich M; Amini E; A Rahman N; Teoh TC; Mohamed Z; Yusof R
PLoS One; 2015; 10(9):e0139248. PubMed ID: 26418816
[TBL] [Abstract][Full Text] [Related]
18. Biologic activities of recombinant human-beta-defensin-4 toward cultured human cancer cells.
Gerashchenko OL; Zhuravel EV; Skachkova OV; Khranovska NN; Filonenko VV; Pogrebnoy PV; Soldatkina MA
Exp Oncol; 2013 Jun; 35(2):76-82. PubMed ID: 23828379
[TBL] [Abstract][Full Text] [Related]
19. A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitro.
Zhao LP; Xu TM; Kan MJ; Xiao YC; Cui MH
Int J Mol Med; 2016 May; 37(5):1310-6. PubMed ID: 27035617
[TBL] [Abstract][Full Text] [Related]
20. Peptide-nanoparticle ligation mediated by cutinase fusion for the development of cancer cell-targeted nanoconjugates.
Galbiati E; Cassani M; Verderio P; Martegani E; Colombo M; Tortora P; Mazzucchelli S; Prosperi D
Bioconjug Chem; 2015 Apr; 26(4):680-9. PubMed ID: 25741889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
